<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20424219</article-id><article-id pub-id-type="pmc">2909051</article-id><article-id pub-id-type="publisher-id">2361</article-id><article-id pub-id-type="doi">10.2337/dc09-2361</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bunck</surname><given-names>Mathijs C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Diamant</surname><given-names>Michaela</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eliasson</surname><given-names>Bjorn</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Corn&#x000e9;r</surname><given-names>Anja</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shaginian</surname><given-names>Rimma M.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Heine</surname><given-names>Robert J.</given-names></name><degrees>MD, PHD, FRCP</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Taskinen</surname><given-names>Marja-Riitta</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>Hannele</given-names></name><degrees>MD, PHD, FRCP</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Ulf</given-names></name><degrees>MD, PHD, FRCP</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><sup>1</sup>Department of Internal Medicine, Section of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands; </aff><aff id="aff2"><sup>2</sup>Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden; </aff><aff id="aff3"><sup>3</sup>Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; </aff><aff id="aff4"><sup>4</sup>Minerva Medical Research Institute, Helsinki, Finland; </aff><aff id="aff5"><sup>5</sup>Eli Lilly and Company, Houten, the Netherlands; </aff><aff id="aff6"><sup>6</sup>Eli Lilly and Company, Indianapolis, Indiana.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Mathijs C. Bunck, <email>mcmbunck@vumc.nl</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>27</day><month>4</month><year>2010</year></pub-date><volume>33</volume><issue>8</issue><fpage>1734</fpage><lpage>1737</lpage><history><date date-type="received"><day>25</day><month>12</month><year>2009</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2010</year></date></history><permissions><copyright-statement>&#x000a9; 2010 by the American Diabetes Association.</copyright-statement><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdc00810001734.pdf"/><abstract><sec><title>OBJECTIVE</title><p>To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers.</p></sec><sec><title>RESEARCH DESIGN AND METHODS</title><p>Metformin-treated patients with type 2 diabetes (<italic>N</italic> = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured.</p></sec><sec><title>RESULTS</title><p>Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%. Insulin glargine significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight.</p></sec><sec><title>CONCLUSIONS</title><p>Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.</p></sec></abstract></article-meta></front><body><p>Abdominal obesity is associated with both type 2 diabetes and metabolic complications (<xref ref-type="bibr" rid="B1">1</xref>), including elevations in several circulating biomarkers of cardiovascular risk (<xref ref-type="bibr" rid="B2">2</xref>). Most pharmacological glucose-lowering treatments increase body weight (<xref ref-type="bibr" rid="B3">3</xref>). Therefore, treatments that not only reduce A1C, but also improve other associated changes such as abdominal obesity are urgently needed (<xref ref-type="bibr" rid="B4">4</xref>).</p><p>We previously reported in <italic>Diabetes Care</italic> that exenatide improves glycemic control to the same extent as insulin glargine, although exenatide decreased and insulin glargine raised body weight (<xref ref-type="bibr" rid="B5">5</xref>). Herein we present additional data on associated changes in body composition and circulating levels of biomarkers of cardiovascular risk after 1 year of treatment.</p><sec><title>RESEARCH DESIGN AND METHODS</title><p>Details on study design were reported previously (<xref ref-type="bibr" rid="B5">5</xref>). Patients were randomized to exenatide (<italic>n</italic> = 36) or insulin glargine (<italic>n</italic> = 33) added to their ongoing metformin therapy (baseline characteristics and patient disposition are shown in supplemental Fig. 1 in the online appendix available at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/cgi/content/full/dc09-2361/DC1">http://care.diabetesjournals.org/cgi/content/full/dc09-2361/DC1</ext-link>). The study protocol was approved by each site's ethics review committee and was in accordance with the principles described in the Declaration of Helsinki. All participating patients gave their written informed consent prior to screening.</p><sec><title>Dual-energy X-ray absorptiometry scan</title><p>Lean body and fat mass was assessed using dual-energy X-ray absorptiometry (DEXA) scans (Delphi A; Hologic, Waltham, MA) at baseline and after treatment. Trunk (abdominal) and limb (hip/leg) regions of interest were determined from a total body scan. Waist circumference was measured at the midline of the interval between the iliac crest and the lowest rib using the mean of two measurements prior to the DEXA scan.</p></sec><sec><title>Biochemical analyses</title><p>Cardiovascular risk biomarkers were collected at baseline and after 1 year of treatment. Serum was separated by centrifugation and stored at &#x02212;80&#x000b0;C until analysis. All serum samples were analyzed in the Lundberg Laboratory for Diabetes Research using a single batch. Total adiponectin, high molecular weight (HMW) adiponectin, resistin, leptin, high-sensitive C-reactive protein (hs-CRP), interleukin (IL)-6, monocyte chemotactic protein (MCP)-1, and endothelin-1 were determined by commercial ELISAs (R&#x00026;D Systems, Abingdon, U.K.).</p></sec><sec><title>Statistical analysis</title><p>Non-normally distributed data were log-transformed prior to statistical analysis, after which they approximated the normal distribution. All outcome measures are compared between the two treatment groups using an ANCOVA model including factors for treatment, investigative site, and baseline A1C stratum (&#x02264;8.5% or &#x0003e;8.5%), and baseline values of corresponding outcome measure as a covariate (<xref ref-type="bibr" rid="B5">5</xref>). Statistical analysis was performed using SPSS 16.0 for Mac OS X (SPSS, Chicago, IL). All inferential statistical tests were conducted at a significance level of 0.05 (two-sided).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Treatment for 1 year with exenatide resulted in a statistically significant reduction in total body fat mass (<xref ref-type="table" rid="T1">Table 1</xref>), mainly in the abdominal region, as illustrated by the decrease in trunk fat mass and waist circumference, in contrast to insulin glargine. Neither treatment significantly affected lean body mass.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Body composition, circulating cardiovascular risk biomarkers and percentage change from baseline</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" colspan="1"/><th align="center" rowspan="2" colspan="1"><italic>n</italic></th><th align="center" rowspan="2" colspan="1">Baseline</th><th align="center" rowspan="2" colspan="1">Endpoint</th><th align="center" colspan="3" rowspan="1">Percentage change from baseline<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">LS mean</th><th align="center" rowspan="1" colspan="1">Between-treatment group difference</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Total fat mass (kg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">29.9 &#x000b1; 1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.5 &#x000b1; 1.9</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1% (&#x02212;7% to +5%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">27.8 &#x000b1; 1.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.4 &#x000b1; 1.6</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;11% (&#x02212;18% to &#x02212;5%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;10% (&#x02212;16% to &#x02212;4%)</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Total lean mass (kg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">60.1 &#x000b1; 1.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">60.6 &#x000b1; 1.8</td><td align="char" char="(" rowspan="1" colspan="1">0% (&#x02212;1% to +2%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57.8 &#x000b1; 2.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">58.1 &#x000b1; 2.4</td><td align="char" char="(" rowspan="1" colspan="1">0% (&#x02212;2% to +1%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1% (&#x02212;3% to +1%)</td><td align="char" char="." rowspan="1" colspan="1">0.480</td></tr><tr><td align="left" rowspan="1" colspan="1">Trunk fat mass (kg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">28</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">17.8 &#x000b1; 0.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16.6 &#x000b1; 1.1</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1% (&#x02212;8% to +5%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">16.3 &#x000b1; 0.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">14.8 &#x000b1; 1.0</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;13% (&#x02212;18 to &#x02212;7%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;11% (&#x02212;18% to &#x02212;4%)</td><td align="char" char="." rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight (kg)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">94.1 &#x000b1; 2.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">93.8 &#x000b1; 2.7</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1% (&#x02212;3% to +1%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">90.3 &#x000b1; 2.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">86.4 &#x000b1; 2.6</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;6% (&#x02212;8% to &#x02212;3%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;5% (&#x02212;7% to &#x02212;2%)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">106.9 &#x000b1; 1.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">107.4 &#x000b1; 2.0</td><td align="char" char="(" rowspan="1" colspan="1">+1% (&#x02212;1% to +3%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">106.1 &#x000b1; 1.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">100.6 &#x000b1; 2.1</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;5% (&#x02212;7% to &#x02212;3%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;6% (&#x02212;8% to &#x02212;4%)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Leptin (&#x003bc;g/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.79 &#x000b1; 1.29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.41 &#x000b1; 1.53</td><td align="char" char="(" rowspan="1" colspan="1">+7% (&#x02212;11% to +29%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.50 &#x000b1; 1.32</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.45 &#x000b1; 1.17</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;14% (&#x02212;27% to +2%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;19% (&#x02212;34% to &#x02212;1%)</td><td align="char" char="." rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">Total adiponectin (ng/ml)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4,648 &#x000b1; 461</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4,508 &#x000b1; 436</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;5% (&#x02212;13% to +5%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">4,848 &#x000b1; 432</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5,314 &#x000b1; 466</td><td align="char" char="(" rowspan="1" colspan="1">+12% (+3% to +21%)</td><td align="char" char="(" rowspan="1" colspan="1">+17% (+6% to +30%)</td><td align="char" char="." rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">HMW adiponectin (ng/ml)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,277 &#x000b1; 221</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,321 &#x000b1; 236</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0% (&#x02212;24% to +31%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,571 &#x000b1; 255</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1,850 &#x000b1; 273</td><td align="char" char="(" rowspan="1" colspan="1">+19% (&#x02212;6% to +51%)</td><td align="char" char="(" rowspan="1" colspan="1">+19% (&#x02212;12% to +61%)</td><td align="char" char="." rowspan="1" colspan="1">0.253</td></tr><tr><td align="left" rowspan="1" colspan="1">hs-CRP (mg/l)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.42 &#x000b1; 0.27</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.38 &#x000b1; 0.35</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;20% (&#x02212;50% to +27%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.81 &#x000b1; 0.25</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.30 &#x000b1; 0.22</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;61% (&#x02212;74% to &#x02212;42%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;52% (&#x02212;71% to &#x02212;19%)</td><td align="char" char="." rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6 (pg/ml)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.96 &#x000b1; 0.21</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.17 &#x000b1; 0.20</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;4% (&#x02212;26% to +25%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.11 &#x000b1; 0.22</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.10 &#x000b1; 0.25</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;10% (&#x02212;28% to +14%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;6% (&#x02212;30% to +26%)</td><td align="char" char="." rowspan="1" colspan="1">0.670</td></tr><tr><td align="left" rowspan="1" colspan="1">MCP-1 (pg/ml)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.22 &#x000b1; 0.07</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.24 &#x000b1; 0.07</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1% (&#x02212;12% to +11%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.18 &#x000b1; 0.09</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.21 &#x000b1; 0.11</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;4% (&#x02212;13% to +7%)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;2% (&#x02212;14% to +12%)</td><td align="char" char="." rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" rowspan="1" colspan="1">Resistin (ng/ml)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">330 &#x000b1; 15</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">329 &#x000b1; 20</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;3% (&#x02212;13% to +7%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">316 &#x000b1; 14</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">311 &#x000b1; 16</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0% (&#x02212;9% to +9%)</td><td align="char" char="(" rowspan="1" colspan="1">+3% (&#x02212;8% to +16%)</td><td align="char" char="." rowspan="1" colspan="1">0.577</td></tr><tr><td align="left" rowspan="1" colspan="1">Endothelin-1 (ng/ml)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Insulin glargine</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.57 &#x000b1; 0.18</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.46 &#x000b1; 0.19</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;7% (&#x02212;11% to &#x02212;2%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Exenatide</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.53 &#x000b1; 0.19</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2.53 &#x000b1; 0.19</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;1% (&#x02212;5% to +3%)</td><td align="char" char="(" rowspan="1" colspan="1">+6% (&#x02212;1% to +12%)</td><td align="char" char="." rowspan="1" colspan="1">0.045</td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SEM (body composition measures) or geometric means &#x000b1; SEM (cardiovascular biomarkers) and body weight change&#x02013;adjusted least-squares mean percentage change (95% CI) from baseline. LS, least-squares.</p></fn></table-wrap-foot></table-wrap><p>In univariate analysis, the reduction in body weight in the exenatide arm was significantly correlated with the changes in leptin (<italic>r</italic> = 0.580, <italic>P</italic> = 0.001) and hs-CRP (<italic>r</italic> = &#x02212;0.590, <italic>P</italic> = 0.001). No statistically significant univariate correlation was found between changes in body weight and other biomarkers. Interestingly, changes in all circulating biomarkers did not correlate with the changes in total body fat mass (total adiponectin: Pearson &#x003c7;<sup>2</sup> test, <italic>r</italic> = &#x02212;0.224, <italic>P</italic> = 0.106; HMW adiponectin: <italic>r</italic> = 0.057, <italic>P</italic> = 0.694; leptin: <italic>r</italic> = 0.229, <italic>P</italic> = 0.106; hs-CRP: <italic>r</italic> = &#x02212;0.023, <italic>P</italic> = 0.872).</p><p>After multivariate analysis and statistical adjustment for body weight change, exenatide increased total adiponectin and decreased hs-CRP concentrations, whereas insulin glargine did not (<xref ref-type="table" rid="T1">Table 1</xref>). Insulin glargine reduced endothelin-1 concentrations, whereas exenatide did not. No statistically significant effect of either treatment on HMW adiponectin, IL-6, MCP-1, and resistin was observed.</p><p>The crude between&#x02013;treatment group differences remained statistically significant after additional multivariate adjustment for total body fat mass change: total adiponectin +16% (95% CI: +5% to +28%), <italic>P</italic> = 0.004; leptin &#x02212;20% (&#x02212;34% to &#x02212;2%), <italic>P</italic> = 0.028; hs-CRP &#x02212;48% (&#x02212;69% to &#x02212;13%), <italic>P</italic> = 0.015; and body weight change (<xref ref-type="table" rid="T1">Table 1</xref>): total adiponectin +17% (95% CI +6% to +30%), <italic>P</italic> = 0.004; leptin &#x02212;19% (&#x02212;34% to 0%), <italic>P</italic> = 0.045; hs-CRP &#x02212;52% (&#x02212;71% to &#x02212;19%), <italic>P</italic> = 0.008.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>This study showed that exenatide reduced body fat mass and improved the profile of circulating cardiovascular biomarkers. The changes in the different biomarkers could not be fully attributed to the observed changes in body fat mass and body weight. Direct effects of glucagon-like peptide 1 (GLP-1) receptor agonists on adipocyte function have been described in both animal experimental studies and in vitro studies in normal human adipocytes (rev. in <xref ref-type="bibr" rid="B6">6</xref>); however, as a significant univariate correlation between change in body weight (not with fat mass) and cardiovascular biomarkers was present, our relatively small population may influence the statistical power of our study.</p><p>Animal studies have also demonstrated beneficial effects of exenatide on visceral fat mass (<xref ref-type="bibr" rid="B7">7</xref>) and circulating adiponectin (<xref ref-type="bibr" rid="B8">8</xref>), leptin (<xref ref-type="bibr" rid="B9">9</xref>), and CRP (<xref ref-type="bibr" rid="B10">10</xref>) concentrations. However, to the best of our knowledge, controlled clinical studies on the long-term effects of GLP-1 receptor agonists on body composition and biomarkers of cardiovascular risk have not previously been reported.</p><p>A recent 3-month study comparing exenatide to insulin glargine in 56 patients with type 2 diabetes has a design comparable to our 1-year study. Similar to our findings, this study showed that exenatide treatment was associated with reduced hs-CRP, without affecting the IL-6 levels (<xref ref-type="bibr" rid="B11">11</xref>).</p><p>Subanalysis of the Liraglutide Effect and Action in Diabetes (LEAD)-3 study data reported that liraglutide treatment for 52 weeks compared with treatment with glimiperide reduced DEXA-measured total fat tissue mass (<xref ref-type="bibr" rid="B12">12</xref>). Lean tissue mass was also reduced after 1 year of treatment, but as glimiperide also reduced lean tissue mass, this reduction was not statistically significantly different between the groups. Twenty-six-week data from the LEAD-2 study was used to show that the observed reduction in fat mass was mainly a result of a reduction in visceral fat (<xref ref-type="bibr" rid="B12">12</xref>). Unfortunately, this study did not report the effects of body composition on circulating biomarkers. Serum leptin, hs-CRP, and IL-6 concentrations did not change in a 14-week placebo-controlled study with liraglutide 1.9 mg (<xref ref-type="bibr" rid="B13">13</xref>).</p><p>Of particular interest in our study was the finding that the changes in biomarkers of cardiovascular risk appeared to be independent of the changes in body fat mass. Recently, Chung et al. reported exendin-4 directly increased adiponectin mRNA levels and secretion in 3T3-L1 adipocytes (<xref ref-type="bibr" rid="B14">14</xref>). In that study, exendin-4 also decreased mRNA levels of IL-6 and MCP-1 (<xref ref-type="bibr" rid="B14">14</xref>). Additionally, we (<xref ref-type="bibr" rid="B15">15</xref>) and others (<xref ref-type="bibr" rid="B10">10</xref>) have previously reported beneficial effects of exenatide on hepatic steatosis, which also may contribute to a reduction in CRP.</p><p>In conclusion, we found that exenatide treatment for 1 year led to a reduced total fat mass, including visceral fat, while lean body mass was not significantly altered. Additionally, the circulating levels of adiponectin, leptin, and hs-CRP showed an improved profile that appeared to be independent of the changes in fat mass. In contrast, no significant changes in body composition or circulating biomarkers were seen with insulin glargine.</p></sec>
      <sec sec-type="supplementary-material">
         <title>Supplementary Material</title>
         <supplementary-material id="PMC_1" content-type="local-data">
            <caption>
               <title>Online Appendix</title>
            </caption>
            <media mimetype="text" mime-subtype="html" xlink:href="supp_33_8_1734__index.html"/>
            <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
                   xlink:href="supp_dc09-2361_onlineappendix.pdf"/>
         </supplementary-material>
      </sec>
   </body><back><fn-group><fn fn-type="other"><p>Clinical trial reg. no. NCT00097500, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group><ack><title>Acknowledgments</title><p>This study was sponsored by Amylin Pharmaceuticals, Inc., and Eli Lilly and Company.</p><p>M.C.B. is a speaker for Eli Lilly and Company. M.D. is a consultant and speaker for Eli Lilly and Company. Through M.D., the VU University Medical Center in Amsterdam has received research grants from Amylin Pharmaceuticals and Eli Lilly and Company. B.E. has served on the advisory board and is a speaker for Eli Lilly Sweden. R.M.S. is an employee of Eli Lilly and Company. R.J.H. is an employee and stockholder of Eli Lilly and Company. M.R.T. is a speaker for Eli Lilly and Company. H.Y.J. serves as a consultant for Amylin Pharmaceuticals. Through M.R.T. and H.Y.J. the Helsinki University Central Hospital has received research grants from Amylin Pharmaceuticals and Eli Lilly and Company. U.S. served on the advisory board and is a speaker for Amylin Pharmaceuticals, Inc. Through U.S. the Sahlgrenska University Hospital has received research grants from Amylin Pharmaceuticals and Eli Lilly and Company.</p><p>No other potential conflicts of interest relevant to this article were reported.</p><p>The study was collectively initiated and designed by the investigators from the three study sites. The investigators had full access to the trial data and had control over the statistical analysis and interpretation of the study results. M.C.B. collected and researched data, wrote the manuscript, and contributed to the discussion. M.D. researched data, contributed to the discussion, and reviewed/edited the manuscript. B.E. collected data, contributed to the discussion, and reviewed/edited the manuscript. A.C. collected data and reviewed/edited the manuscript. R.M.S. contributed to discussion and reviewed/edited the manuscript. R.J.H. researched data, contributed to the discussion, and reviewed/edited the manuscript. M.R.T. contributed to the discussion and reviewed/edited the manuscript. H.Y.J. contributed to the discussion and reviewed/edited the manuscript. U.S. researched data, contributed to the discussion, and reviewed/edited the manuscript.</p><p>Parts of this study were presented in abstract form at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5&#x02013;9 June 2009.</p><p>The authors thank the subjects for participating in the study.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MD</given-names></name></person-group> <article-title>Role of body fat distribution and the metabolic complications of obesity</article-title>. <source>J Clin Endocrinol Metab</source><year>2008</year>;<volume>93</volume>:<fpage>S57</fpage>&#x02013;<lpage>63</lpage><pub-id pub-id-type="pmid">18987271</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Lamb</surname><given-names>HJ</given-names></name><name><surname>van de Ree</surname><given-names>MA</given-names></name><name><surname>Endert</surname><given-names>EL</given-names></name><name><surname>Groeneveld</surname><given-names>Y</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>Kostense</surname><given-names>PJ</given-names></name><name><surname>Radder</surname><given-names>JK</given-names></name></person-group> <article-title>The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source><year>2005</year>;<volume>90</volume>:<fpage>1495</fpage>&#x02013;<lpage>1501</lpage><pub-id pub-id-type="pmid">15613416</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group</article-title>. <source>Lancet</source><year>1998</year>;<volume>352</volume>:<fpage>837</fpage>&#x02013;<lpage>853</lpage><pub-id pub-id-type="pmid">9742976</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defronzo</surname><given-names>RA</given-names></name></person-group> <article-title>Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus</article-title>. <source>Diabetes</source><year>2009</year>;<volume>58</volume>:<fpage>773</fpage>&#x02013;<lpage>795</lpage><pub-id pub-id-type="pmid">19336687</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunck</surname><given-names>MC</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Corn&#x000e9;r</surname><given-names>A</given-names></name><name><surname>Eliasson</surname><given-names>B</given-names></name><name><surname>Malloy</surname><given-names>JL</given-names></name><name><surname>Shaginian</surname><given-names>RM</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Kendall</surname><given-names>DM</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Smith</surname><given-names>U</given-names></name><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name></person-group> <article-title>One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial</article-title>. <source>Diabetes Care</source><year>2009</year>;<volume>32</volume>:<fpage>762</fpage>&#x02013;<lpage>768</lpage><pub-id pub-id-type="pmid">19196887</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Egan</surname><given-names>JM</given-names></name></person-group> <article-title>The role of incretins in glucose homeostasis and diabetes treatment</article-title>. <source>Pharmacol Rev</source><year>2008</year>;<volume>60</volume>:<fpage>470</fpage>&#x02013;<lpage>512</lpage><pub-id pub-id-type="pmid">19074620</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szayna</surname><given-names>M</given-names></name><name><surname>Doyle</surname><given-names>ME</given-names></name><name><surname>Betkey</surname><given-names>JA</given-names></name><name><surname>Holloway</surname><given-names>HW</given-names></name><name><surname>Spencer</surname><given-names>RG</given-names></name><name><surname>Greig</surname><given-names>NH</given-names></name><name><surname>Egan</surname><given-names>JM</given-names></name></person-group> <article-title>Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats</article-title>. <source>Endocrinology</source><year>2000</year>;<volume>141</volume>:<fpage>1936</fpage>&#x02013;<lpage>1941</lpage><pub-id pub-id-type="pmid">10830274</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Boden</surname><given-names>G</given-names></name></person-group> <article-title>Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels</article-title>. <source>Diabetes Obes Metab</source><year>2008</year>;<volume>10</volume>:<fpage>921</fpage>&#x02013;<lpage>930</lpage><pub-id pub-id-type="pmid">18093209</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Tilve</surname><given-names>D</given-names></name><name><surname>Gonz&#x000e1;lez-Mat&#x000ed;as</surname><given-names>L</given-names></name><name><surname>Alvarez-Crespo</surname><given-names>M</given-names></name><name><surname>Leiras</surname><given-names>R</given-names></name><name><surname>Tovar</surname><given-names>S</given-names></name><name><surname>Di&#x000e9;guez</surname><given-names>C</given-names></name><name><surname>Mallo</surname><given-names>F</given-names></name></person-group> <article-title>Exendin-4 potently decreases ghrelin levels in fasting rats</article-title>. <source>Diabetes</source><year>2007</year>;<volume>56</volume>:<fpage>143</fpage>&#x02013;<lpage>151</lpage><pub-id pub-id-type="pmid">17192476</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Saxena</surname><given-names>NK</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>NA</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Anania</surname><given-names>FA</given-names></name></person-group> <article-title>Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice</article-title>. <source>Hepatology</source><year>2006</year>;<volume>43</volume>:<fpage>173</fpage>&#x02013;<lpage>181</lpage><pub-id pub-id-type="pmid">16374859</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>ES</given-names></name><name><surname>Cohen</surname><given-names>A</given-names></name><name><surname>Gibson</surname><given-names>H</given-names></name><name><surname>Lamparello</surname><given-names>B</given-names></name><name><surname>Herzlinger</surname><given-names>S</given-names></name><name><surname>McFarland</surname><given-names>L</given-names></name></person-group> <article-title>Effects of exenatide vs insulin glargine on cardiovascular risk factors in subjects with type 2 diabetes</article-title>. <source>Diabetologia</source><year>2009</year>;<volume>52</volume>:<fpage>S298</fpage>&#x02013;<lpage>S299</lpage></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jendle</surname><given-names>J</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Frid</surname><given-names>A</given-names></name><name><surname>Hermansen</surname><given-names>K</given-names></name><name><surname>D&#x000fc;ring</surname><given-names>M</given-names></name><name><surname>Zdravkovic</surname><given-names>M</given-names></name><name><surname>Strauss</surname><given-names>BJ</given-names></name><name><surname>Garber</surname><given-names>AJ</given-names></name></person-group>: <collab>LEAD-2 and LEAD-3 Study Groups</collab> <article-title>Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue</article-title>. <source>Diabetes Obes Metab</source><year>2009</year>;<volume>11</volume>:<fpage>1163</fpage>&#x02013;<lpage>1172</lpage><pub-id pub-id-type="pmid">19930006</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courr&#x000e8;ges</surname><given-names>JP</given-names></name><name><surname>Vilsb&#x000f8;ll</surname><given-names>T</given-names></name><name><surname>Zdravkovic</surname><given-names>M</given-names></name><name><surname>Le-Thi</surname><given-names>T</given-names></name><name><surname>Krarup</surname><given-names>T</given-names></name><name><surname>Schmitz</surname><given-names>O</given-names></name><name><surname>Verhoeven</surname><given-names>R</given-names></name><name><surname>Bug&#x000e1;&#x000f1;ov&#x000e1;</surname><given-names>I</given-names></name><name><surname>Madsbad</surname><given-names>S</given-names></name></person-group> <article-title>Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes</article-title>. <source>Diabet Med</source><year>2008</year>;<volume>25</volume>:<fpage>1129</fpage>&#x02013;<lpage>1131</lpage><pub-id pub-id-type="pmid">19183322</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim Chung le</surname><given-names>T</given-names></name><name><surname>Hosaka</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>N</given-names></name><name><surname>Sakaue</surname><given-names>H</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Nakaya</surname><given-names>Y</given-names></name></person-group> <article-title>Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression</article-title>. <source>Biochem Biophys Res Commun</source><year>2009</year>;<volume>390</volume>:<fpage>613</fpage>&#x02013;<lpage>618</lpage><pub-id pub-id-type="pmid">19850014</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tushuizen</surname><given-names>ME</given-names></name><name><surname>Bunck</surname><given-names>MC</given-names></name><name><surname>Pouwels</surname><given-names>PJ</given-names></name><name><surname>van Waesberghe</surname><given-names>JH</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name></person-group> <article-title>Incretin mimetics as a novel therapeutic option for hepatic steatosis</article-title>. <source>Liver Int</source><year>2006</year>;<volume>26</volume>:<fpage>1015</fpage>&#x02013;<lpage>1017</lpage><pub-id pub-id-type="pmid">16953843</pub-id></mixed-citation></ref></ref-list></back></article>